Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
André J. Scheen. (2022) Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism & Toxicology 18:6, pages 381-393.
Read now
Read now
Sze Wa Chan, Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2021) The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk. Pharmaceutical Biology 59:1, pages 1159-1169.
Read now
Read now
Genya Aharon-Hananel & Itamar Raz. (2019) An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opinion on Pharmacotherapy 20:7, pages 781-790.
Read now
Read now
Mattia Galli, Domenico D’Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea & Nadia Aspromonte. (2018) Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1273-1285.
Read now
Read now
André J. Scheen. (2018) The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 17:8, pages 837-848.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Liraglutide for weight management: benefits and risks. Current Medical Research and Opinion 33:3, pages 537-539.
Read now
Read now
Articles from other publishers (10)
Hemat El-Sayed El-Horany, Marwa Mohamed Atef, Muhammad Tarek Abdel Ghafar, Mohamed. H. Fouda, Nahla Anas Nasef, Islam Ibrahim Hegab, Duaa S. Helal, Walaa Elseady, Yasser Mostafa Hafez, Rasha Youssef Hagag, Monira Abdelmoaty Seleem, Mai Mahmoud Saleh, Doaa A. Radwan, Amal Ezzat Abd El-Lateef & Rania Nagi Abd-Ellatif. (2023) Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy. International Journal of Molecular Sciences 24:11, pages 9481.
Crossref
Crossref
Xiaoling Li, Benedikt Preckel, Jeroen Hermanides, Markus W. Hollmann, Coert J. Zuurbier & Nina C. Weber. (2022) Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection. British Journal of Pharmacology 179:16, pages 4047-4062.
Crossref
Crossref
Tahira Khan, Bushra Nabi, Saleha Rehman, Mohd. Akhtar, Javed Ali & Abul Kalam Najmi. (2021)
Quality by Design Approach to Formulate Empagliflozin-Loaded Chitosan Nanoparticles:
In Vitro
,
In Vivo
and Pharmacokinetic Evaluation of Anti-Diabetic Drugs
. Nano 16:13.
Crossref
Crossref
Sevil Korkmaz-Icöz, Cenk Kocer, Alex A. Sayour, Patricia Kraft, Mona I. Benker, Sophia Abulizi, Adrian-Iustin Georgevici, Paige Brlecic, Tamás Radovits, Sivakkanan Loganathan, Matthias Karck & Gábor Szabó. (2021) The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats. International Journal of Molecular Sciences 22:15, pages 7774.
Crossref
Crossref
Hye Jung Park, Heejae Han, Eun-Yi Oh, Sung Ryeol Kim, Kyung Hee Park, Jae-Hyun Lee & Jung-Won Park. (2019) Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model. Scientific Reports 9:1.
Crossref
Crossref
Mortaza F. Hassanabad & Zahra F.H. Abad. (2019) Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:3, pages 1893-1896.
Crossref
Crossref
Wendy L. St. Peter, Lori Wazny & Joanna Q. Hudson. 2019. Chronic Kidney Disease, Dialysis, and Transplantation. Chronic Kidney Disease, Dialysis, and Transplantation
250
272.e5
.
Sarayut Lahnwong, Siriporn C. Chattipakorn & Nipon Chattipakorn. (2018) Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovascular Diabetology 17:1.
Crossref
Crossref
M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder & R. E. Schmieder. (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovascular Diabetology 17:1.
Crossref
Crossref
Bassam M. Ayoub, Shereen Mowaka, Eman S. Elzanfaly, Nermeen Ashoush, Mohamed M. Elmazar & Shaker A. Mousa. (2017) Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations. Scientific Reports 7:1.
Crossref
Crossref